ID: ALA5182536

Max Phase: Preclinical

Molecular Formula: C18H17FN2O

Molecular Weight: 296.35

Representations

Canonical SMILES:  C#CCN(Cc1ccc(F)cc1)c1ccc(NC(C)=O)cc1

Standard InChI:  InChI=1S/C18H17FN2O/c1-3-12-21(13-15-4-6-16(19)7-5-15)18-10-8-17(9-11-18)20-14(2)22/h1,4-11H,12-13H2,2H3,(H,20,22)

Standard InChI Key:  BUMGEENUXQEBJR-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 296.35

Molecular Weight (Monoisotopic): 296.1325

AlogP: 3.42

#Rotatable Bonds: 5

Polar Surface Area: 32.34

Molecular Species: NEUTRAL

HBA: 2

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 3

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa:

CX LogP: 3.41

CX LogD: 3.41

Aromatic Rings: 2

Heavy Atoms: 22

QED Weighted: 0.86

Np Likeness Score: -1.78

References

1. Zhang YM, Xu HY, Hu HN, Tian FY, Chen F, Liu HN, Zhan L, Pi XP, Liu J, Gao ZB, Nan FJ..  (2021)  Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.,  64  (9.0): [PMID:33929863] [10.1021/acs.jmedchem.0c02252]

Source

Source(1):

• Scientific Literature